Trial Profile
An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 3277511 (Primary)
- Indications Chronic obstructive pulmonary disease; Respiratory tract disorders
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 24 Apr 2019 Results published in the Vaccine
- 06 Apr 2017 Status changed from active, no longer recruiting to completed.
- 03 Apr 2017 Planned End Date changed from 1 Mar 2017 to 3 Apr 2017.